8-K Announcements
6Material company update
Jun 15, 2026·SEC
Material company update
Jun 10, 2026·SEC
Material company update
May 7, 2026·SEC
enGene Holdings Inc.(ENGN)Earnings, Financials & Key Ratios
ENGN•NASDAQ
$1.92
Price updated Jul 7, 2026
AboutenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Show more
- Revenue$0
- EBITDA-$123M-97.9%
- Net Income-$117M-112.7%
- EPS (Diluted)-2.29-56.8%
- ROE-53.28%-66.7%
ENGN Price & Volume
enGene Holdings Inc. (ENGN) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical Burn Threatens Capital Runway Stability
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
Key Thesis Takeaways
- enGene Holdings remains a high-risk, pre-revenue biotechnology firm heavily reliant on the successful progression of its LEGEND clinical trial to justify its valuation.
- While the company continues to advance its proprietary DDX delivery platform, the rapid depletion of cash reserves from $264.8 million in 2024Q2 to $29.8 million in 2026Q2 suggests an urgent need for additional capital.
- Investors should monitor the company's ability to manage its $432.0 million accumulated deficit against the backdrop of escalating quarterly R&D expenditures that reached $22.2 million in 2026Q2.
Verdict Logic
the company's cash reserves have plummeted to $29.8 million as of 2026Q2, creating a precarious liquidity position that likely necessitates dilutive financing to sustain ongoing clinical operations.
ENGN Growth Metrics
enGene Holdings Inc. (ENGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-109.52%
Return on Capital
10 Years-27.01%
5 Years-27.01%
3 Years-36.04%
Last Year-50.69%
ENGN Recent Earnings
enGene Holdings Inc. (ENGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (45%)
Q3 2026Latest
Jun 15, 2026Metric
Actual
Est
EPS
$0.43+10.4%
$0.48
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.44+20.0%
$0.55
Rev
—
—
Q4 2025
Dec 22, 2025Metric
Actual
Est
EPS
$0.73-28.8%
$0.57
Rev
—
—
Q4 2025
Sep 11, 2025Metric
Actual
Est
EPS
$0.57-14.5%
$0.50
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 15, 2026 | $0.43vs $0.48+10.4% | — |
| Q2 2026 | Mar 9, 2026 | $0.44vs $0.55+20.0% | — |
| Q4 2025 | Dec 22, 2025 | $0.73vs $0.57-28.8% | — |
| Q4 2025 | Sep 11, 2025 | $0.57vs $0.50-14.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for enGene Holdings Inc. (ENGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.92 | $98.29M | -0.84 | — | — | -53.28% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $16.15 | $984.9M | -8.83 | -5.55% | -529.67% | -11.85% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — |
Compare ENGN vs Peers
enGene Holdings Inc. (ENGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENGN SEC Filings & Documents
enGene Holdings Inc. (ENGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ENGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENGN Frequently Asked Questions
enGene Holdings Inc. (ENGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ENGN profitable?
enGene Holdings Inc. (ENGN) reported a net loss of $66.4M for fiscal year 2025.
Dividend & Returns
What is ENGN's return on equity?
enGene Holdings Inc. (ENGN) has a return on equity (ROE) of -53.3%. Negative ROE indicates the company is unprofitable.
What is enGene Holdings Inc.'s free cash flow?
enGene Holdings Inc. (ENGN) had negative free cash flow of $111.4M in fiscal year 2025, likely due to heavy capital investments.